On Jan. 14, 2008, Merck/Schering-Plough released the results of a drug trial intended to prove the claim and show a correlation between lowered LDL levels and fatty plaques in the arteries, which can cause heart attacks and strokes.
While the study once again showed that Vytorin lowered LDL cholesterol rates better than Zocor alone, it also showed that the fatty arterial plaques actually grew somewhat faster in patients taking Zetia along with Zocor than in those taking Zocor alone.
The suit also calls into question the timing of the study's release. According to published reports, the two-year drug trial concluded April 2006 but wasn't announced until Jan. 15, 2008. According to the complaint, Merck and Schering-Plough knew the results of the trials but delayed sharing the findings with patients and did not change its marketing approach.
Zetia and Vytorin account for combined sales of $1.1 billion during the fourth quarter of 2007. The agreement with Merck and Schering-Plough provided that the companies split profits roughly 50-50, depending on regions.
The suit seeks the return of money to purchasers of Vytorin and Zetia, which the study shows are no more effective than the generic form of Zocor. The lawsuit will not seek relief for personal injuries that anyone may allege resulted from taking Vytorin or Zetia.
Visit http://www.hbsslaw.com/zetia.htm to read a more comprehensive background document or view the complaint. You can also contact plaintiff's attorneys, Steve Berman or Craig Spiegel at 206-623-7292 or via e-mail at firstname.lastname@example.org.
About Hagens Berman Sobol Shapiro
Hagens Berman Sobol Shapiro is based in Seattle with offices in
Chicago, Cambridge, Los Angeles, Phoenix and San Francisco. Since 1993, it
has developed a nationally recognized practice in class-action and complex
litigation. Among recent successes, HBSS has ne
|SOURCE Hagens Berman Sobol Shapiro|
Copyright©2008 PR Newswire.
All rights reserved